Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors: A Series of Systematic Reviews and Meta-analyses of Randomized Controlled Trials
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Established therapeutic lipid targets - HDL-cholesterol
研究概览
简要总结
Obesity is a major risk factor for cardiovascular disease and diabetes. Weight loss is an important therapeutic goal for overweight and obese patients to reduce their risk of developing cardiovascular disease and diabetes. Liquid meal replacements (LMRs) are simple tools that may aid in weight loss and may improve weight-related risk cardiometabolic risk factors. There is a need to synthesize the evidence on LMRs and cardiometabolic risk to inform clinical practice guidelines. The authors propose to conduct a series of systematic review and meta-analysis of randomized controlled trials to evaluate the effect of LMRs on 4 areas of cardiometabolic risk: markers of adipsoity, glycemic control, established lipid targets, and blood pressure.
详细描述
Background: Liquid meal replacements (LMRs) provide a mixture of carbohydrate, fat and protein, along with added vitamins and minerals in liquid ready-to-drink form or powder formulas that require mixing. They are designed to mimic a low-calorie meal and serve as a quick and easy source of calories to consume. Behavioral strategy tools are important to assist obese individuals in losing weight and maintaining weight loss. There is evidence that LMRs contribute to weight loss and may reduce related cardiometabolic risk factors.
Need for proposed research: An earlier meta-analysis demonstrated that partial meal replacement plans produced significant weight loss and improved weight-related cardiometabolic risk factors. Several controlled trials have since investigated the effect of liquid meal replacements on body weight and weight-related risk factors for disease. There is a need to update of the evidence of the effect of LMRs on cardiometabolic risk to inform dietary guidelines and public health policy development.
Objective: To synthesize the evidence of randomized controlled trials of the effect of LMRs on body weight, blood pressure, glycemic control and established lipid targets.
Design: The systematic review and meta-analysis will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Data sources: MEDLINE, EMBASE and The Cochrane Central Register of Controlled Trials (Clinical Trials; CENTRAL) will be searched using appropriate search terms supplemented by manual searches.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Trials in humans
- •Liquid meal replacement intervention
- •Presence of a comparator diet (control diet)
- •Diet duration >=2 weeks
- •Viable outcome data
排除标准
- •Non-human trials
- •Observational studies
- •Lack of suitable comparator diet
- •No viable outcome data
结局指标
主要结局
Established therapeutic lipid targets - HDL-cholesterol
时间窗: Up to 20 years
HDL-cholesterol (HDL-C)
Established therapeutic lipid targets - triglycerides
时间窗: Up to 20 years
Triglycerides
Blood pressure - systolic blood pressure
时间窗: Up to 20 years
Systolic blood pressure
Markers of adiposity - body weight
时间窗: Up to 20 years
Body weight
Markers of adiposity - Body Mass Index
时间窗: Up to 20 years
Body Mass Index (BMI)
Markers of adiposity - body fat
时间窗: Up to 20 years
Body fat
Markers of adiposity - waist circumference
时间窗: Up to 20 years
Waist circumference
Glycemic control - HbA1c
时间窗: Up to 20 years
HbA1c
Glycemic control - fasting glucose
时间窗: Up to 20 years
fasting glucose
Glycemic control - fasting insulin
时间窗: Up to 20 years
fasting insulin
Established therapeutic lipid targets - LDL-cholesterol
时间窗: Up to 20 years
LDL-cholesterol (LDL-C)
Established therapeutic lipid targets - apolipoprotein B
时间窗: Up to 20 years
Apolipoprotein B (apo B)
Established therapeutic lipid targets - non-HDL-cholesterol
时间窗: Up to 20 years
non-HDL-cholesterol (non-HDL-C)
Blood pressure - diastolic blood pressure
时间窗: Up to 20 years
Diastolic blood pressure
次要结局
未报告次要终点
研究者
John Sievenpiper
Associate Professor
University of Toronto
